SARS-CoV-2

[ScienceInsider] Opening a new chapter in the treatment of COVID-19—one borrowed from successfully tackling the AIDS virus—the drug behemoth Pfizer reported upbeat results for a 5-day pill regimen to treat early infections with SARS-CoV-2.

[Proceedings of the National Academy of Sciences of the United States of America] Investigators showed that O-glycosylation near the furin cleavage site was mediated by members of the GALNT enzyme family, resulting in decreased furin cleavage and decreased syncytia formation.

[Proceedings of the National Academy of Sciences of the United States of America] The authors targeted white-tailed deer for serosurveillance based on evidence these deer have angiotensin-converting enzyme 2 receptors with high affinity for SARS-CoV-2.

[Scientific Reports] Researchers evaluated novel protein subunit vaccine formulations containing a resistin-trimerized spike antigen, SmT1.

[Science] Investigators reported the discovery and characterization of PF-07321332, an orally bioavailable SARS-CoV-2 main protease inhibitor with in vitro pan-human coronavirus antiviral activity and excellent off-target selectivity and in vivo safety profiles.

[Science Immunology] Researchers monitored T cell responses to the Spike protein of SARS-CoV-2 in 71 healthy donors vaccinated with two doses of the Pfizer–BioNTech mRNA vaccine for up to six months after vaccination.